Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

475
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
475

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spatial immune profiling characterizes tumor microenvironment heterogeneity between metastatic and nonmetastatic cutaneous squamous cell carcinoma in organ transplant patients.

The Journal of investigative dermatology·2026
Same author

Prediction of Mutations and Outcome in Gastrointestinal Stromal Tumors with Deep Learning: A Multicenter, Multinational Study.

medRxiv : the preprint server for health sciences·2026
Same author

International multicenter retrospective study on pleomorphic rhabdomyosarcoma (P-RMS), a PUSH platform study: outcome of primary localized disease.

ESMO open·2026
Same author

PSMA expression and PSMA PET/CT imaging in metastatic soft tissue sarcoma patients, results of a prospective study.

European journal of nuclear medicine and molecular imaging·2025
Same author

PENGUIN: A rapid and efficient image preprocessing tool for multiplexed spatial proteomics.

Computational and structural biotechnology journal·2024
Same author

Low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, outcome of advanced disease: retrospective study from the Ultra-Rare Sarcoma Working Group.

ESMO open·2024

Related Experiment Video

Updated: Jun 4, 2025

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

9.1K

Immunological differences between monophasic and biphasic synovial sarcoma with implications for immunotherapy.

S J Luk1, M E IJsselsteijn2, A Somarakis3

  • 1Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands. s.j.luk@lumc.nl.

Cancer Immunology, Immunotherapy : CII
|December 21, 2024
PubMed
Summary

Biphasic synovial sarcoma, a soft-tissue cancer, shows distinct immune cell infiltration compared to monophasic types. Higher T-cell presence in primary tumors correlates with better patient survival, suggesting potential for T-cell-based immunotherapies.

Keywords:
Adoptive T-cell therapyImmunotherapySarcomaSurvivalSynovial sarcomaT-cell therapy

More Related Videos

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

6.9K
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

8.9K

Related Experiment Videos

Last Updated: Jun 4, 2025

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

9.1K
Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

6.9K
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

8.9K

Area of Science:

  • Oncology
  • Immunology
  • Soft Tissue Pathology

Background:

  • Synovial sarcoma is an aggressive soft-tissue cancer with poor response to current immunotherapies.
  • Understanding the tumor microenvironment's immune cell composition is crucial for improving treatment strategies.

Purpose of the Study:

  • To investigate the immune infiltrate in synovial sarcoma concerning histological subtype, disease progression, and response to treatment.
  • To determine if specific immune cell populations or their spatial distribution correlate with patient outcomes and therapeutic susceptibility.

Main Methods:

  • Immunodetection of T cells, CD68+ myeloid cells, endothelial cells, and keratin in 41 synovial sarcoma patient samples.
  • Analysis of immune cell distribution relative to tumor histology (biphasic vs. monophasic) and disease stage.
  • Correlation of immune cell infiltration with patient survival and response to cytotoxic therapies.

Main Results:

  • Synovial sarcoma immune microenvironment is dominated by CD68+ myeloid cells, with increased CD163+ immunosuppressive cells after therapy.
  • Biphasic synovial sarcomas exhibit higher T-cell and myeloid cell infiltration than monophasic types.
  • Immune and endothelial cells are localized in the stromal compartment, excluded from epithelial areas, similar to healthy tissues.

Conclusions:

  • Biphasic synovial sarcoma possesses a distinct immune profile compared to monophasic, suggesting potential for enhanced immunotherapy response.
  • Intratumoral T-cell infiltration in primary tumors is linked to improved overall survival, indicating a potential anti-tumor role.
  • Findings support exploring adoptive T-cell therapy for biphasic synovial sarcoma.